Inogen Inc
NASDAQ:INGN

  • LAST PRICE
    9.7800
  • TODAY'S CHANGE (%)
    0.4000 (4.2644%)
  • Bid / Lots
    9.4000/ 1
  • Ask / Lots
    10.1100/ 45
  • Open / Previous Close
    9.4400 / 9.3800
  • Day Range
    9.3500
    9.8400
  • 52 Week Range
    4.9300
    13.3299
  • Volume
    300,564

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 4:16PM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: INGN
      04:16 PM EST, 11/07/2024 (MT Newswires) -- ...

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: INGN
      Payment of employment taxes related to release of restricted stock (286) (504) ------- ------- Net cash provided by financing activities 525 974 ------- ------- Effect of exchange rates on cash (153) 149 ------- ------- Net decrease in cash, cash equivalents and restricted cash $(16,211) $(62,406) ------- ------- Supplemental Financial Information (unaudited) (in thousands, except units and patients) Constant Three months ended Currency September 30, Change 2024 vs. 2023 Change ------------------ -------------------- ---------- Revenue by region and category 2024 2023 $ % % ---------------------- -------- -------- --------- --------- ---------- Business-to-business domestic sales $ 23,352 $ 17,288 $ 6,064 35.1% 35.1% Business-to-business international sales 32,328 25,613 6,715 26.2% 26.9% Direct-to-consumer domestic sales 19,249 25,072 (5,823) -23.2% -23.2% Direct-to-consumer domestic rentals 13,905 15,994 (2,089) -13.1% -13.1% ------- ------- ------- ----- ------ Total revenue $ 88,834 $ 83,967 $ 4,867 5.8% 6.0% ======= ======= ======= ===== ====== Additional financial measures Units Sold 43,900 35,400 Net rental patients as of period-end 51,400 51,900 Constant Nine months ended Currency September 30, Change 2024 vs. 2023 Change ------------------ -------------------- ---------- Revenue by region and category 2024 2023 $ % % ---------------------- -------- -------- --------- --------- ---------- Business-to-business domestic sales $ 61,158 $ 48,145 $ 13,013 27.0% 27.0% Business-to-business international sales 88,894 67,877 21,017 31.0% 30.8% Direct-to-consumer domestic sales 62,397 76,181 (13,784) -18.1% -18.1% Direct-to-consumer domestic rentals 43,175 47,561 (4,386) -9.2% -9.2% ------- ------- ------- ----- ------ Total revenue $255,624 $239,764 $ 15,860 6.6% 6.6% ======= ======= ======= ===== ====== Additional financial measures Units Sold 119,100 96,400 Net rental patients as of period-end 51,400 51,900 Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures (unaudited) (in thousands) Three months ended Nine months ended September 30, September 30, -------------------- ---------------------- Non-GAAP EBITDA and Adjusted EBITDA 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Net loss (GAAP) $ (5,963) $(45,719) $(26,131) $(75,894) Non-GAAP adjustments: Interest income, net (1,041) (1,801) (3,777) (4,972) Provision (benefit) for income taxes (101) 401 (258) 638 Depreciation and amortization 5,314 4,614 15,924 13,008 ------- ------- ------- ------- EBITDA (non-GAAP) (1,791) (42,505) (14,242) (67,220) Stock-based compensation 1,474 1,779 5,704 8,484 Acquisition-related expenses 127 960 784 1,981 Restructuring-related and other charges -- 1,416 -- 3,426 Impairment charges -- 32,894 -- 32,894 Change in fair value of earnout liability 650 -- 1,830 -- ------- ------- ------- ------- Adjusted EBITDA (non-GAAP) $ 460 $ (5,456) $ (5,924) $(20,435) ======= ======= ======= ======= Three months ended September 30, -------------------------------------------- Net Loss Diluted EPS -------------------- ---------------------- Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Financial Results (GAAP) $ (5,963) $(45,719) $ (0.25) $ (1.97) Non-GAAP adjustments: Amortization of intangibles 1,107 205 Stock-based compensation 1,474 1,779 Acquisition-related expenses 127 960 Restructuring-related and other charges (1) -- 1,416 Impairment charges -- 32,894 Change in fair value of earnout liability 650 -- Income tax impact of adjustments (2) -- -- ------- ------- --------- ----------- Adjusted $ (2,605) $ (8,465) $ (0.11) $ (0.36) ======= ======= ======= ======= Nine months ended September 30, -------------------------------------------- Net Loss Diluted EPS -------------------- ---------------------- Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Financial Results (GAAP) $(26,131) $(75,894) $ (1.11) $ (3.28) Non-GAAP adjustments: Amortization of intangibles 3,227 284 Stock-based compensation 5,704 8,484 Acquisition-related expenses 784 1,981 Restructuring-related and other charges (1) -- 3,426 Impairment charges -- 32,894 Change in fair value of earnout liability 1,830 -- Income tax impact of adjustments (2) -- -- ------- ------- --------- ----------- Adjusted $(14,586) $(28,825) $ (0.62) $ (1.25) ======= ======= ======= ======= (1) Charges represent the costs associated with workforce reductions and other restructuring-related activities. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for the three and nine months ended September 30, 2024 and 2023.

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: INGN
      Payment of employment taxes related to release of restricted stock (286) (504) ------- ------- Net cash provided by financing activities 525 974 ------- ------- Effect of exchange rates on cash (153) 149 ------- ------- Net decrease in cash, cash equivalents and restricted cash $(16,211) $(62,406) ------- ------- Supplemental Financial Information (unaudited) (in thousands, except units and patients) Constant Three months ended Currency September 30, Change 2024 vs. 2023 Change ------------------ -------------------- ---------- Revenue by region and category 2024 2023 $ % % ---------------------- -------- -------- --------- --------- ---------- Business-to-business domestic sales $ 23,352 $ 17,288 $ 6,064 35.1% 35.1% Business-to-business international sales 32,328 25,613 6,715 26.2% 26.9% Direct-to-consumer domestic sales 19,249 25,072 (5,823) -23.2% -23.2% Direct-to-consumer domestic rentals 13,905 15,994 (2,089) -13.1% -13.1% ------- ------- ------- ----- ------ Total revenue $ 88,834 $ 83,967 $ 4,867 5.8% 6.0% ======= ======= ======= ===== ====== Additional financial measures Units Sold 43,900 35,400 Net rental patients as of period-end 51,400 51,900 Constant Nine months ended Currency September 30, Change 2024 vs. 2023 Change ------------------ -------------------- ---------- Revenue by region and category 2024 2023 $ % % ---------------------- -------- -------- --------- --------- ---------- Business-to-business domestic sales $ 61,158 $ 48,145 $ 13,013 27.0% 27.0% Business-to-business international sales 88,894 67,877 21,017 31.0% 30.8% Direct-to-consumer domestic sales 62,397 76,181 (13,784) -18.1% -18.1% Direct-to-consumer domestic rentals 43,175 47,561 (4,386) -9.2% -9.2% ------- ------- ------- ----- ------ Total revenue $255,624 $239,764 $ 15,860 6.6% 6.6% ======= ======= ======= ===== ====== Additional financial measures Units Sold 119,100 96,400 Net rental patients as of period-end 51,400 51,900 Reconciliation of U.S. GAAP to Other Non-GAAP Financial Measures (unaudited) (in thousands) Three months ended Nine months ended September 30, September 30, -------------------- ---------------------- Non-GAAP EBITDA and Adjusted EBITDA 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Net loss (GAAP) $ (5,963) $(45,719) $(26,131) $(75,894) Non-GAAP adjustments: Interest income, net (1,041) (1,801) (3,777) (4,972) Provision (benefit) for income taxes (101) 401 (258) 638 Depreciation and amortization 5,314 4,614 15,924 13,008 ------- ------- ------- ------- EBITDA (non-GAAP) (1,791) (42,505) (14,242) (67,220) Stock-based compensation 1,474 1,779 5,704 8,484 Acquisition-related expenses 127 960 784 1,981 Restructuring-related and other charges -- 1,416 -- 3,426 Impairment charges -- 32,894 -- 32,894 Change in fair value of earnout liability 650 -- 1,830 -- ------- ------- ------- ------- Adjusted EBITDA (non-GAAP) $ 460 $ (5,456) $ (5,924) $(20,435) ======= ======= ======= ======= Three months ended September 30, -------------------------------------------- Net Loss Diluted EPS -------------------- ---------------------- Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Financial Results (GAAP) $ (5,963) $(45,719) $ (0.25) $ (1.97) Non-GAAP adjustments: Amortization of intangibles 1,107 205 Stock-based compensation 1,474 1,779 Acquisition-related expenses 127 960 Restructuring-related and other charges (1) -- 1,416 Impairment charges -- 32,894 Change in fair value of earnout liability 650 -- Income tax impact of adjustments (2) -- -- ------- ------- --------- ----------- Adjusted $ (2,605) $ (8,465) $ (0.11) $ (0.36) ======= ======= ======= ======= Nine months ended September 30, -------------------------------------------- Net Loss Diluted EPS -------------------- ---------------------- Non-GAAP Adjusted Net Loss and Diluted EPS 2024 2023 2024 2023 ------------------------ --------- --------- --------- ----------- Financial Results (GAAP) $(26,131) $(75,894) $ (1.11) $ (3.28) Non-GAAP adjustments: Amortization of intangibles 3,227 284 Stock-based compensation 5,704 8,484 Acquisition-related expenses 784 1,981 Restructuring-related and other charges (1) -- 3,426 Impairment charges -- 32,894 Change in fair value of earnout liability 1,830 -- Income tax impact of adjustments (2) -- -- ------- ------- --------- ----------- Adjusted $(14,586) $(28,825) $ (0.62) $ (1.25) ======= ======= ======= ======= (1) Charges represent the costs associated with workforce reductions and other restructuring-related activities. (2) Income tax impact of adjustments represents the tax impact related to the non-GAAP adjustments listed above and reflects an effective tax rate of 0% for the three and nine months ended September 30, 2024 and 2023.

    • 4:04PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: SGHT, INGN

      release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

  • Nov 4, 2024

Peers Headlines